Articles tagged with Neuroblastoma
Researchers at The Children's Hospital of Philadelphia have discovered a new gene, LMO1, as a significant contributor to neuroblastoma, the most common solid cancer of early childhood. Variants in this gene increase the risk of developing aggressive forms of neuroblastoma and mark the gene for continued disease progression.
A new study found that black children are more likely to have the high-risk form of neuroblastoma and show signs of resistance to modern treatment. The study also showed disparities in outcome according to race, with black patients having a lower survival rate than white patients.
A new clinical trial found that 96% of patients with intermediate-risk neuroblastoma survived for three years after receiving reduced chemotherapy doses. The study, led by Katherine Matthay at UCSF Benioff Children's Hospital, aimed to minimize the toxic effects of cancer drugs on young children.
A new immunotherapy treatment has improved two-year survival rates for high-risk neuroblastoma patients by 20 percent compared to standard treatment. Researchers report a higher cure rate, but also more pain and toxic side effects.
The addition of immunotherapy to standard therapy increases the percentage of children with high-risk neuroblastoma who are alive and free of disease progression after two years. The new regimen, which targets a substance on tumor cells called GD2, presents a clear paradigm shift in treating this cancer.
Recent advances in neuroblastoma research have led to a better understanding of the disease's genetic landscape, including common DNA variations on chromosome 6 and mutations in the ALK gene. Innovative therapies such as immunotherapy trials using monoclonal antibodies and cytokines are also being explored.
New research published in the FASEB Journal suggests that DHA and its derivatives can effectively kill neuroblastoma and other cancer cells. The study found that toxic byproducts of DHA were even more effective at killing cancer cells, providing a promising new avenue for anti-cancer treatment.
Researchers at the University of Gothenburg have used novel technology to analyze the genetic patterns of neuroblastoma, an aggressive form of childhood cancer. The discovery may lead to significant advances in treatment, enabling tailor-made treatments for sub-groups of the most aggressive cases.
Researchers have identified NT-3 and its binding molecule TrkC as potential therapeutic targets for treating neuroblastoma. The study found that blocking the interaction between NT-3 and TrkC inhibited tumor growth and metastasis in animal models.
In this study, researchers discovered autoantibodies that target the natural protein Trib2 in narcolepsy patients with cataplexy, indicating that narcolepsy may be an autoimmune disorder. Additionally, a team of researchers identified a potential therapeutic target for neuroblastoma by studying human neuroblastoma cells and mice.
Researchers found that nutlin-3 activates the p53 pathway and suppresses tumor growth in mice models of chemoresistant neuroblastoma. Oral administration of nutlin-3 as a single agent reduced tumor growth and metastasis, providing a potential treatment option for advanced-stage and chemoresistant neuroblastoma.
A new study found that positron emission tomography (PET) can accurately depict the extent of neuroblastoma in some patients, especially those with early-stage disease. FDG-PET imaging may also be useful in identifying malignant lesions not readily absorbable by MIBG.
Neuroblastoma survivors are eight times more likely to have chronic health conditions and less likely to be married or employed with high income compared to their siblings. Late mortality, second malignant tumors, and chronic health conditions were analyzed in a study of 954 survivors diagnosed between 1970-1986.
Researchers at Keio University found that matrix metalloproteinases improve wound healing in mice, while a complement inhibitor FUT-175 delays autoimmune disease onset. Additionally, a new target for tumor angiogenesis inhibition and bone morphogenic protein-7 (BMP-7) have been identified as potential therapies for liver high blood pre...
A genetic glitch called copy number variation in a single chromosome is associated with neuroblastoma. Researchers have identified this link, which could lead to the development of targeted therapies for the disease.
Two new studies have identified genetic events that increase a child's susceptibility to high-risk neuroblastoma. Common variants in the BARD1 gene and a specific copy number variation at chromosome 1q21.1 are found to be associated with the development of this childhood cancer.
A team of researchers identified astrocyte elevated gene-1 (AEG-1) as a critical gene that regulates tumor progression in neuroblastoma, a form of cancer commonly found in young children. Loss of AEG-1 was shown to reduce the tumor-causing properties of aggressive neuroblastoma cells.
Researchers have developed a new therapy that uses elements of the immune system to improve cure rates for children with high-risk neuroblastoma. The treatment showed a 20% increase in preventing relapse and a greater cure rate compared to standard therapy.
A phase III study found that adding an antibody-based therapy improved the survival rate of children with high-risk neuroblastoma by 66%, increasing their chances of living disease-free for at least two years. The therapy targets a specific glycan on cancer cells, enabling immune cells to attack and kill them.
Researchers at the University of Texas M. D. Anderson Cancer Center have discovered a new drug that inhibits neuroblastoma blood supply, reducing tumor growth by 75%. The drug, AMD3100, blocks interaction between SDF-1a and its receptor CXCR4, preventing tumors from growing rapidly by disrupting their blood supply.
A new study has identified a biomarker, ZNF423, associated with poor outcome in neuroblastoma, the most common childhood cancer. Reduced expression of ZNF423 was linked to increased growth and resistance to differentiation in tumor cells.
Researchers at Scripps Florida have found a novel use for the old compound α-difluoromethylornithine (DFMO) in treating high-risk neuroblastoma. The study showed that even low doses of the drug could prevent cancer in animal models.
Researchers identified a key role for the kinase Aurora A in stabilizing N-Myc, a primary driver of aggressive childhood cancer. The findings suggest that targeting Aurora A may not be effective in inhibiting cancer growth, highlighting the need for new therapeutic approaches.
A new global evaluation system for neuroblastoma has been recommended to improve treatment outcomes for children. The system, developed by the International Neuroblastoma Risk Group, will enable quicker identification of optimal treatments and facilitate clinical research.
Researchers at Dana-Farber Cancer Institute identified five new mutations in the ALK gene responsible for growth and survival signals in neuroblastoma cells. A small molecule inhibitor, TAE684, halted proliferation and brought on cell death in test cells with these mutations.
Researchers at the University of Florida have discovered a way to short-circuit genetic processes that contribute to neuroblastomas. By targeting the ALK gene, they found that certain mutations can be sensitive to a small molecule inhibitor, potentially leading to new drug treatments.
Scientists have discovered gene mutations that cause inherited neuroblastoma, the most common childhood cancer. The mutations also play a significant role in high-risk non-inherited forms of the disease, leading to new testing opportunities and potential targeted therapies.
Researchers at the University of Texas Medical Branch have found that shutting down gastrin-releasing peptide receptors can dramatically suppress neuroblastoma tumor formation and slow its spread. This breakthrough could lead to the development of new therapies for this devastating disease.
A study by Children's Hospital of Philadelphia researchers identified a chromosome region that predisposes children to developing neuroblastoma, a fatal childhood cancer. The discovery could lead to the development of novel treatments and better interventions.
Researchers developed a tumor-targeting viral therapy that slowed the growth of neuroblastoma and peripheral nerve sheath tumors by inhibiting tissue growth and reducing blood vessel formation. The treatment, called rQT3, showed promise in laboratory studies and improved life spans in mice with these types of tumors.
Scientists have found a promising anti-cancer drug candidate in HC-toxin, isolated from a fungal maize pathogen. The substance inhibits histone deacetylases, altering genetic material packaging and reducing cancer cell properties.
Researchers at St. Jude Children's Research Hospital discovered that treating tumors with bevacizumab first and then administering topotecan therapy after improved tumor blood flow can significantly reduce cancer growth, holding promise for improving treatment for children with neuroblastoma.
Researchers have made progress in treating neuroblastoma, a difficult pediatric cancer, with new approaches such as radioactive isotopes and targeted therapies. However, further understanding of the disease's precise biology is needed to guide optimal treatment choices.
Researchers discuss future directions in neuroblastoma treatment, including new approaches for high-risk patients and the development of an international classification system. Current regimens and prognosis are also analyzed, highlighting the need for improved understanding of genomic alterations to guide therapy.
Scientists have discovered that an attenuated form of poliovirus can effectively destroy neuroblastoma tumors in mice without harming them. The study's findings suggest that this approach could represent a new, safe means of treating childhood cancer and potentially other cancers in adults.
Researchers at St. Jude Children's Research Hospital and City of Hope National Medical Center developed genetically modified stem cells that seek out and destroy even tiny tumors in the nervous system, using a chemotherapy drug that selectively targets cancer cells.
A 55-gene expression profile identifies children at high risk of progressive metastatic neuroblastoma. Lay health advisors improve mammography use among low-income women. Cyclin D1 inhibits STAT3, slowing breast cancer tumor growth. Researchers identify CD95/CD95L as a molecular system involved in radiation-induced pneumonitis.
Researchers found that STAT1 expression was lower in SCCHN tumors than in normal tissue, and increasing STAT1 expression led to suppressed tumor growth. The study also suggests that STAT1 works as a tumor suppressor for SCCHN cells, but when its expression is lowered, SCCHN tumors grow.
Researchers found that the loss of caspase-8 protein promotes neuroblastoma metastasis by allowing cancer cells to break away from the primary tumor and spread to other sites in the body. Novel treatments that restore the tumor-suppression role of caspase-8 may prevent metastases and improve patient outcomes.
Researchers analyzed tumor samples from 915 children with neuroblastoma and identified genetic clues that can guide customized treatment. The study found strong links between loss of genetic material on chromosome bands 1p36 and 11q23, and worse outcomes for patients.
A study evaluated the Quebec Neuroblastoma Screening Project and found that not implementing screening programs saved $574.1 million in unnecessary health costs. The study also found that widespread use of neuroblastoma screening across North America would have caused adverse health effects.
A new technique using a customized gene chip can rapidly detect genetic changes in neuroblastoma tumors, helping doctors predict treatment outcomes and guide therapy. The approach may also be adapted for other types of cancer with DNA changes important to their prognosis.
A team of researchers will use a comprehensive approach to tackle neuroblastoma, aiming to develop new treatments and potentially prevent the disease. The study will focus on understanding the molecular basis of neuroblastoma and identifying compounds that can inhibit cancer growth.
Researchers identified chromosome 11q deletion as a significant predictor of high-risk neuroblastoma, with 66% overall survival rate. The deletion removes tumor suppressor gene protective effect, allowing tumor growth.
A phase 2 trial of MIBG therapy shows an overall response rate of 35 percent in children with refractory or relapsed neuroblastoma. The treatment selectively targets tumor cells and has a lower risk of toxic effects on blood cells compared to conventional treatments.
Researchers tested a weakened version of herpes simplex virus against neuroblastoma tumors, with only the virus proving effective in treating the cancer. The study shows promise for using the therapy in children and potentially in other cancers as well.
Researchers have identified novel compounds that show promise in treating neuroblastoma and glucose-deprived tumors, while also developing new assays to measure the effectiveness of immunotherapy. Additionally, scientists outline best methods for determining the health benefits of diet and exercise.
A meta-analysis of six studies found autologous bone marrow transplantation to be more effective in disease-free survival but similar overall survival compared to chemotherapy. Imatinib also shows promise as a treatment for advanced neuroblastoma, while tamoxifen use is linked to increased risk of rare uterine cancers.
Researchers found a significant decline in neuroblastoma diagnoses after the mandatory folic acid food fortification program was introduced. The study suggests that maternal folic acid intake may play a role in preventing this aggressive and deadly form of childhood cancer.
A new study found that a rapid increase in the incidence of esophageal and gastric cardia adenocarcinomas is linked to modifiable risk factors such as smoking, being overweight, and gastroesophageal reflux. High serum levels of vitamin E are associated with reduced risk of upper gastrointestinal cancers.
A new trial found that a radioactive compound called MIBG can not only image but also help kill neuroblastoma tumors. In the Phase I trial, 11 children with advanced neuroblastoma had positive responses and few side effects when treated with MIBG combined with chemotherapy and bone marrow transplant.
A nationwide consortium of nine institutions aims to improve treatment outcomes for children with neuroblastoma by testing new therapies and sharing research information. The project has already shown promising results in improving disease-free survival rates and may lead to faster development of effective treatments.
A large-scale study found that infant screening for neuroblastoma fails to detect the most severe form of the disease in nearly 500,000 Canadian infants. The researchers conclude that some cases of neuroblastoma detected by screening may resolve spontaneously or fail to progress.